Wolfgang Landgraf

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Mesenchymal Stem Cells

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

This page only lists publications with an associated author ORCID identifier.

Publications

Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Responses to Basal Insulin Glargine (300 U/mL and 100 U/mL) with or Without Pre-prandial Insulin in Pre-treated Subphenotypes of Type 2 Diabetes: Insights from a Post Hoc Analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders 15 (8) (2024)
Wolfgang Landgraf, David R Owens, Brian M Frier, Geremia B Bolli
Treatment responses to basal insulin glargine 300 U/ml and glargine 100 U/ml in newly defined subphenotypes of type 2 diabetes: A post hoc analysis of the EDITION 3 randomized clinical trial. Diabetes, obesity & metabolism (2023)
Robert Ritzel, Sujoy Ghosh, Rifat Emral, Rachid Malek, Longyi Zeng, Maria Aileen Mabunay, Wolfgang Landgraf, Patricia Guyot, Paul Serafini, Divya Pushkarna, Rayaz Ahmed Malik
Comparative efficacy and safety of Gla-300 versus IDegAsp in insulin-naïve people with type 2 diabetes mellitus uncontrolled on oral anti-diabetics. Diabetes, obesity & metabolism (2023)
Geremia B Bolli, Wolfgang Landgraf, Zsolt Bosnyak, Lydie Melas-Melt, Philip D Home
Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naïve people with type 2 diabetes: A post hoc analysis of the EDITION 3 trial. Diabetes, obesity & metabolism 22 (9) (2020)
David R Owens, Wolfgang Landgraf, Brian M Frier, Mei Zhang, Philip D Home, Stephen H Mandy, Geremia B Bolli
Commencing insulin glargine 100 U/mL therapy in individuals with type 2 diabetes: Determinants of achievement of HbA1c goal less than 7.0. Diabetes, obesity & metabolism 21 (2) (2019)
Wolfgang Landgraf, David R Owens, Brian M Frier, Mei Zhang, Geremia B Bolli
Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naïve people with type 2 diabetes initiating basal insulin glargine 100 U/mL. Diabetes, obesity & metabolism 22 (3) (2019)